Chris Brady, Shelly Steele<sup>1</sup>, Lindsey Christy<sup>1</sup>, Mike Cioffi, Amee Patel<sup>1</sup>, Dorothee Schoemaker<sup>1</sup>, Lydia Hatfield<sup>1</sup>, Jacqueline French, Bree DiVentura<sup>3</sup>, Meryl Lozano<sup>3</sup>

# **Development and Content Validation of a Seizure** eDiary Optimized for Clinical Trials: A Partnership with Industry Epilepsy Experts

## Methodological Question Being Asked

Can an innovative seizure electronic diary (eDiary) be developed to be fit for purpose across protocol and target population needs and user friendly for patients, caregivers and investigators?

include minor rewording (i.e., changing "Individual or Multiple Countable Seizure(s)" to "One or More Countable Seizures") and formatting (i.e., changed the use of symbols ">" and "<" to number ranges) (Figure 4). No significant usability problems were encountered during usability testing, and subjects reported liking some of the features (insights page). Usability testing results include six suggested minor modifications; three will be addressed in training and three are preferential (Figure 5). Suggested changes include additional text for clarity (e.g., add date to "My tasks" page) and formatting (e.g., increase font size or change colors) (Figure 6).

### Introduction (Aims)

Clinical trials in epilepsy typically evaluate seizure frequency and type (among other variables) to determine a treatment effect. Historically this information has been collected using a patient completed paper diary. It has been established that electronic data collection offers benefits over paper due to eliminating manual transcription of source data into the EDC database, availability of an audit trail, time stamped entries and ability to complete assessments on one's personal device [Bring Your Own Device (BYOD)]. To leverage the well-documented advantages of electronic data collection, industry scientific and technological experts worked with the Epilepsy Study Consortium, Inc. (ESCI) Working Group comprised of members of the ESCI, key opinion leaders in epilepsy clinical trials, and pharmaceutical company representatives to design a new seizure eDiary.

Seizure Diary	4:17 ? ■ = Insight ?	TYPE OF SEIZURES COLLECTED	SELECT FROM ILAE CLASSIFICATON LIBRARY
April 25th 2023 Record Seizure	Congratulations!	Clusters	Include: Yes or No
nell & taste, flashing lights,	25 <sub>/45</sub> 55	Count	Number of seizures
PM - 5:59 PM) 1	25   Days without seizures     Days with seizures	Duration	Length of seizure
AM) day	Seizure Diary - Rescue Medication  Days without	Timeframe	Approximate time seizure occurred
	DAYS Days with rescue medication	Collection of rescue	Include: Yes or No



Figure 3: Cognitive Debriefing Outcome of **Suggested Modifications** 

Figure 4: Cognitive Debriefing Suggested Change and Outcome



Figure 1: Diary Summary and Insight Pages

Table 1: General Diary Configuration Options

### Methods

Input from the Working Group guided the creation of initial eDiary mockups, followed by iterative feedback cycles. Following the initial development, formal semi-structured qualitative interviews were conducted with a representative sample of ten individuals with epilepsy and ten individuals who are caregivers of patients with epilepsy (Table 2). Interviews involved two stages: (1) cognitive debriefing to ensure that the instructions and content of the eDiary are relevant and comprehensible and (2) usability testing to evaluate the ease of use of the eDiary (Figure 2). This is in line with regulatory agencies' emphasis on the importance of the patient voice and best practices in Patient-Reported Outcome (PRO) development.



Figure 5: Cognitive Debriefing Outcome of Outcome

Figure 6: Usability Testing Suggested Change and

#### Conclusions

Suggested Modifications

The qualitative research provided supportive evidence for the usability and content validity of the Seizure eDiary to capture information about subjects' seizure experiences to evaluate the efficacy of an investigational product in clinical trials. Minor changes may be considered over time to further improve data capture and ease of use. Confirmation of ease of use and improved data quality will be undertaken once the Seizure eDiary is implemented.

PARTICIPANTS	NUMBER	YEARS WITH DIAGNOSIS <i>MEAN (SD</i> )	SEX N (%)	AGE IN YEARS <i>MEAN (SD</i> )	EDUCATION IN YEARS <i>MEAN (SD)</i>		
Adults with epilepsy diagnosis	10	28 (9.7)	Female 5 (50%)	44 (15.9)	14 (1.6)		
			Male 5 (50%)				
Caregivers	10	20 (0 4)	Female 5 (50%)	44 (15.7)	13 (4.3)		
		20 (9.4)	Male 5 (50%)				
ble 2. Summer of Derticipent Characteristics							



Table 2: Summary of Participant Characteristics

Figure 2: Cognitive Debriefing and Usability Testing Process

#### Results

Users reported no major issues regarding the relevance or appropriateness of the eDiary instructions or content. Twenty-one minor modifications were suggested during cognitive debriefing; eighteen were implemented, two will be addressed in training and one was preferential (Figure 3). Suggested changes

#### Disclosures

Chris Brady, Shelly Steele, Lindsey Christy, Mike Cioffi, Amee Patel, Dorothee Schoemaker, Lydia Hatfield are all full-time employees of WCG.

#### References

Coons SJ, Eremenco S, Lundy JJ, O'Donohoe P, O'Gorman H, Malizia W. Capturing Patient-Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO Measurement in Clinical Trials. Patient. 2015 Aug;8(4):301-9. doi: 10.1007/s40271-014-0090-z. Erratum in: Patient. 2015 Dec;8(6):571. PMID: 25300613; PMCID: PMC4529477.

Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for Purpose Clinical Outcome Assessments. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. June 2022. Available at:

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-foc used-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome